AR126727A1 - Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4 - Google Patents
Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4Info
- Publication number
- AR126727A1 AR126727A1 ARP220102119A ARP220102119A AR126727A1 AR 126727 A1 AR126727 A1 AR 126727A1 AR P220102119 A ARP220102119 A AR P220102119A AR P220102119 A ARP220102119 A AR P220102119A AR 126727 A1 AR126727 A1 AR 126727A1
- Authority
- AR
- Argentina
- Prior art keywords
- nucleic acid
- sequence
- recombinant nucleic
- mitochondrial
- protein
- Prior art date
Links
- 230000035772 mutation Effects 0.000 title 1
- 201000001119 neuropathy Diseases 0.000 title 1
- 230000007823 neuropathy Effects 0.000 title 1
- 230000003287 optical effect Effects 0.000 title 1
- 208000033808 peripheral neuropathy Diseases 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 6
- 102000006404 Mitochondrial Proteins Human genes 0.000 abstract 5
- 108010058682 Mitochondrial Proteins Proteins 0.000 abstract 5
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 108091026890 Coding region Proteins 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 abstract 2
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 abstract 2
- 230000002438 mitochondrial effect Effects 0.000 abstract 2
- 241000702421 Dependoparvovirus Species 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000013603 viral vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/864—Parvoviral vectors, e.g. parvovirus, densovirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporciona un ácido nucleico recombinante que comprende: una secuencia mitocondrial diana; y una secuencia de codificación de una proteína mitocondrial, en la cual la secuencia de codificación de una proteína mitocondrial codifica un polipéptido que comprende una proteína mitocondrial; una secuencia del ácido nucleico del extremo 3 UTR, y una secuencia señal de poliA. También se proporciona una composición farmacéutica que comprende el ácido nucleico recombinante y un método para el tratamiento de la neuropatía óptica hereditaria de Leber (NOHL) utilizando la composición farmacéutica. Reivindicación 1: Un ácido nucleico recombinante que comprende (secuencialmente desde el extremo 5 hasta el extremo 3) una secuencia mitocondrial diana y una secuencia de codificación de una proteína mitocondrial, en el cual, opcionalmente, la secuencia de codificación de una proteína mitocondrial codifica una proteína ND4; y, opcionalmente, la proteína ND4 comprende una secuencia de aminoácidos que tiene al menos un 90%, al menos un 95%, al menos un 96%, al menos un 97%, al menos un 98%, al menos un 99% o un 100% de identidad con la SEC ID Nº 160. Reivindicación 32: Un vector viral que comprende el ácido nucleico recombinante según cualquiera de las reivindicaciones 1 a 31. Reivindicación 35: Una composición farmacéutica que comprende un virus adenoasociado (AAV), en el cual el AAV comprende el ácido nucleico recombinante según cualquiera de las reivindicaciones 1 a 31.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110899561 | 2021-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126727A1 true AR126727A1 (es) | 2023-11-08 |
Family
ID=85155306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102119A AR126727A1 (es) | 2021-08-06 | 2022-08-05 | Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4 |
Country Status (7)
| Country | Link |
|---|---|
| KR (1) | KR20240042489A (es) |
| CN (1) | CN116024266A (es) |
| AR (1) | AR126727A1 (es) |
| AU (1) | AU2022322957A1 (es) |
| BR (1) | BR112024002305A2 (es) |
| CA (1) | CA3228344A1 (es) |
| WO (1) | WO2023011632A1 (es) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
| EP0318512B1 (en) | 1986-08-18 | 1998-06-17 | Emisphere Technologies, Inc. | Delivery systems for pharmacological agents |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| CA2153391C (en) | 1993-01-11 | 2000-08-15 | Kenneth Rock | Inducing cytotoxic t lymphocyte responses |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| CN102634527B (zh) * | 2012-04-11 | 2013-11-06 | 华中科技大学同济医学院附属同济医院 | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 |
| CN113476484A (zh) * | 2018-06-29 | 2021-10-08 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| CN111068071A (zh) * | 2018-10-22 | 2020-04-28 | 武汉纽福斯生物科技有限公司 | 基因治疗Leber遗传学视神经病变 |
| WO2020001657A1 (en) * | 2018-06-29 | 2020-01-02 | Wuhan Neurophth Biological Technology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| KR20210068014A (ko) * | 2018-08-20 | 2021-06-08 | 우한 뉴로프스 바이오테크놀로지 리미티드 컴퍼니 | 레버 유전성 시신경병증의 치료를 위한 조성물 및 방법 |
-
2022
- 2022-08-05 WO PCT/CN2022/110545 patent/WO2023011632A1/zh active Application Filing
- 2022-08-05 BR BR112024002305A patent/BR112024002305A2/pt unknown
- 2022-08-05 CN CN202210938308.5A patent/CN116024266A/zh active Pending
- 2022-08-05 AR ARP220102119A patent/AR126727A1/es unknown
- 2022-08-05 AU AU2022322957A patent/AU2022322957A1/en active Pending
- 2022-08-05 CA CA3228344A patent/CA3228344A1/en active Pending
- 2022-08-05 KR KR1020247007322A patent/KR20240042489A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023011632A1 (zh) | 2023-02-09 |
| CN116024266A (zh) | 2023-04-28 |
| CA3228344A1 (en) | 2023-02-09 |
| AU2022322957A1 (en) | 2024-03-21 |
| KR20240042489A (ko) | 2024-04-02 |
| BR112024002305A2 (pt) | 2024-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096027A2 (es) | Proteínas insecticidas quiméricas de bacillus thuringiensis | |
| PE20220930A1 (es) | Composiciones utiles en el tratamiento de leucodistrofia metacromatica | |
| DE69430071T2 (de) | Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem | |
| AR047347A1 (es) | Miembros de la familia cry9 de bacillus | |
| RU95115239A (ru) | Аналог эритропоэтина | |
| AR062019A1 (es) | Gen de bacillus thuringiensis con actividad contra lepidopteros | |
| ES2061996T3 (es) | Regiones no esenciales de avipoxvirus. | |
| MX9202512A (es) | Virus de avipox recombinante, cultivo de celulas infectadas por este virusy vacunas para las aves de corral derivadas de este virus. | |
| PE20220429A1 (es) | Vectores viricos que codifican variantes del fviii recombinantes con mayor expresion para la genoterapia de la hemofilia a | |
| CL2020000295A1 (es) | Métodos de terapia génica del factor viii (fviii) | |
| MX2022006949A (es) | Composiciones y metodos para tratar la neuropatia optica hereditaria de leber con proteinas nadh deshidrogenasa. | |
| RU2017127276A (ru) | Рекомбинантные гликопротеины с сиалированными о-гликанами и линии клеток для их продукции | |
| PT97965A (pt) | Processo para a preparacao de novos fragmentos peptidicos, de sequencias de dna que os codificam,de moleculas de dna que as contem e plantas transgenicas que compreendem tais moleculas | |
| MX2020013772A (es) | Composiciones y métodos para el tratamiento de la neuropatía óptica hereditaria de leber. | |
| BR112022004027A2 (pt) | Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte | |
| EP3916005A3 (en) | Immunogenic composition | |
| AR126396A1 (es) | VARIANTES DESOPTIMIZADAS DE SARS-CoV-2 Y MÉTODOS Y USOS DE LAS MISMAS | |
| AR126727A1 (es) | Composición y método para tratar la neuropatía óptica hereditaria de leber causada por la mutación nd4 | |
| PE20240915A1 (es) | Composiciones y metodos para tratar la enfermedad de fabry | |
| CO2024002315A2 (es) | Sistemas de edición de gen que comprenden una guía de arn dirigida a estatmina 2 (stmn2) y usos de los mismos | |
| ES2063383T3 (es) | Vacunas contra la coccidiosis. | |
| DK200800635A (da) | Hidtil ukendt fiskelusvaccine. | |
| PE20212072A1 (es) | Composiciones utiles en el tratamiento de la enfermedad de krabbe | |
| AR122379A1 (es) | Composiciones inmunogénicas y vacunas de covid-19 vectorizadas con sarampión | |
| AR005771A1 (es) | Polipeptidos con actividad de mutanasa, secuencias de acidos nucleicos que los codifican, construccion de acidos nucleicos, vector de expresionrecombinante, celula huesped recombinante, metodos para producir los polipeptidos, polipeptido hibrido y uso de dichos polipeptidos para preparar |